tyrosine and vorinostat

tyrosine has been researched along with vorinostat in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Augenlicht, L; Huang, J; Klampfer, L; Swaby, LA	1
Bu, Q; Cui, L; Ding, K; Du, X; Li, J; Pan, J; Zou, W	1

Other Studies

2 other study(ies) available for tyrosine and vorinostat

Article	Year
Requirement of histone deacetylase activity for signaling by STAT1. The Journal of biological chemistry, 2004, Jul-16, Volume: 279, Issue:29 Topics: Active Transport, Cell Nucleus; Apoptosis; bcl-X Protein; Blotting, Western; Butyrates; Cell Line; Cell Line, Tumor; Cell Nucleus; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gene Expression Regulation; Gene Silencing; Genes, Reporter; Histone Deacetylase 1; Histone Deacetylase 2; Histone Deacetylases; Humans; Hydroxamic Acids; Inflammation; Interferon-gamma; Microscopy, Fluorescence; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Repressor Proteins; RNA Interference; RNA, Small Interfering; Serine; Signal Transduction; STAT1 Transcription Factor; Trans-Activators; Transcriptional Activation; Transfection; Tyrosine; Vorinostat	2004
SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells. Cancer biology & therapy, 2014, Volume: 15, Issue:7 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Humans; Hydroxamic Acids; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Tyrosine; Vorinostat	2014

Article

Year

Requirement of histone deacetylase activity for signaling by STAT1.

The Journal of biological chemistry, 2004, Jul-16, Volume: 279, Issue:29

Topics: Active Transport, Cell Nucleus; Apoptosis; bcl-X Protein; Blotting, Western; Butyrates; Cell Line; Cell Line, Tumor; Cell Nucleus; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gene Expression Regulation; Gene Silencing; Genes, Reporter; Histone Deacetylase 1; Histone Deacetylase 2; Histone Deacetylases; Humans; Hydroxamic Acids; Inflammation; Interferon-gamma; Microscopy, Fluorescence; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Repressor Proteins; RNA Interference; RNA, Small Interfering; Serine; Signal Transduction; STAT1 Transcription Factor; Trans-Activators; Transcriptional Activation; Transfection; Tyrosine; Vorinostat

2004

SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.

Cancer biology & therapy, 2014, Volume: 15, Issue:7

Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Humans; Hydroxamic Acids; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Tyrosine; Vorinostat

2014